Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Several studies have provided ample evidence of a clinically significant interobserver variation of the histological diagnosis of glioma. This interobserver variation has an effect on both the typing and grading of glial tumors. Since treatment decisions are based on histological diagnosis and grading, this affects patient care: erroneous classification and grading may result in both over- and undertreatment. In particular, the radiotherapy dosage and the use of chemotherapy are affected by tumor grade and lineage. It also affects the conduct and interpretation of clinical trials on glioma, in particular of studies into grade II and grade III gliomas. Although trials with central pathology review prior to inclusion will result in a more homogeneous patient population, the interpretation and external validity of such trials are still affected by this, and the question whether results of such trials can be generalized to patients diagnosed and treated elsewhere remains to be answered. Although molecular classification may help in typing and grading tumors, as of today this is still in its infancy and unlikely to completely replace histological classification. Routine pathology review in everyday clinical practice should be considered. More objective histological criteria for the grade and lineage of gliomas are urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Histologic diagnosis and grading of gliomas have been limited by considerable intra- and interobserver variability (42).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the grading criteria in the current classification schema for oligodendrogliomas continues to predominantly rely upon histopathologic examination; the differentiating criterion between grade 2 and grade 3 oligodendrogliomas are the presence of conspicuous microvascular proliferation and/or 6 mitoses per 10 high-power field [3,4,5,6,7,8,9,10,11].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“Importantly, these data further facilitate consensus ratings on radiology images (e.g., MRI) of expert radiologists to alleviate inconsistencies that often arise due to subjective impressions and inter- and intra-observer variability [229].”
From AI in Medical Imaging Informatics: Current Challenges and Future Directions (2020) · cites this paper as [229]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Feinstein, A. R., Sosin, D. M., & Wells, C. K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198506203122504 · Cited by 1,544
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Nutt, C. L., Mani, D. R., Betensky, R. A., Tamayo, P., Cairncross, J. G., Ladd, C., Pohl, U., Hartmann, C. J., McLaughlin, M. E., Batchelor, T. T., et al. (2003) · PubMed · Cited by 959
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Smith, J. S., Perry, A., Borell, T. J., Lee, H. K., O’Fallon, J., Hosek, S. M., Kimmel, D., Yates, A., Burger, P. C., Scheithauer, B. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.636 · Cited by 804
van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J. B., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 748
Research works printed but not linked: 1
- Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1391 · doi:10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w
Cited by
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab200 · Cited by 2,529
Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,189
Ostrom, Q. T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., & Barnholtz-Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy131 · Cited by 2,138
Ostrom, Q. T., Gittleman, H., Liao, P., Vecchione-Koval, T., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox158 · Cited by 1,800
Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa200 · Cited by 1,789
Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac202 · Cited by 1,565
Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad149 · Cited by 1,294
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Ostrom, Q. T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now207 · Cited by 1,204
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Predicting cancer outcomes from histology and genomics using convolutional networks
Mobadersany, P., Yousefi, S., Amgad, M., Gutman, D. A., Barnholtz-Sloan, J. S., Velázquez Vega, J. E., Brat, D. J., & Cooper, L. A. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717139115 · Cited by 1,084
Hartmann, C., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0781-z · Cited by 829
AI in Medical Imaging Informatics: Current Challenges and Future Directions
Panayides, A. S., Amini, A., Filipovic, N. D., Sharma, A., Tsaftaris, S. A., Young, A., Foran, D., Do, N., Golemati, S., Kurc, T., et al. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.2991043 · Cited by 713
Genetic and molecular epidemiology of adult diffuse glioma
Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0220-2 · Cited by 709
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Price, M., Ballard, C., Benedetti, J., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., Barnholtz-Sloan, J. S., & Ostrom, Q. T. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae145 · Cited by 526
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J. G., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 460
Patel, S. H., Poisson, L. M., Brat, D. J., Zhou, Y., Cooper, L., Snuderl, M., Thomas, C., Franceschi, A. M., Griffith, B., Flanders, A. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0560 · Cited by 424
Olar, A., Wani, K. M., Alfaro-Munoz, K. D., Heathcock, L. E., van Thuijl, H. F., Gilbert, M. R., Armstrong, T. S., Sulman, E. P., Cahill, D. P., Vera-Bolanos, E., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1398-z · Cited by 354
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 350
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Wijnenga, M. M. J., French, P. J., Dubbink, H. J., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Smits, M., Gahrmann, R., Rutten, G.-J., Verheul, J. B., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox176 · Cited by 334
Ostrom, Q. T., Price, M., Ryan, K., Edelson, J., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac161 · Cited by 321
Weller, M., Weber, R. G., Willscher, E., Riehmer, V., Hentschel, B., Kreuz, M., Felsberg, J., Beyer, U., Löffler-Wirth, H., Kaulich, K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1409-0 · Cited by 312
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
Artificial Intelligence in Lung Cancer Pathology Image Analysis
Wang, S., Yang, D. M., Rong, R., Zhan, X., Fujimoto, J., Liu, H., Minna, J., Wistuba, I. I., Xie, Y., & Xiao, G. (2019) · Cancers · doi:10.3390/cancers11111673 · Cited by 291
Artificial Intelligence in Medicine: Where Are We Now?
Kulkarni, S., Seneviratne, N., Baig, M. S., & Khan, A. H. A. (2020) · Academic Radiology · doi:10.1016/j.acra.2019.10.001 · Cited by 282
Isocitrate dehydrogenase mutations in gliomas
Waitkus, M. S., Diplas, B. H., & Yan, H. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 282
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
Arita, H., Yamasaki, K., Matsushita, Y., Nakamura, T., Shimokawa, A., Takami, H., Tanaka, S., Mukasa, A., Shirahata, M., Shimizu, S., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0351-2 · Cited by 252
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision
KOMORI, T. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2017-0010 · Cited by 247
Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007
Leece, R., Xu, J., Ostrom, Q. T., Chen, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox091 · Cited by 235
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Butowski, N., Fenstermaker, R. A., Forsyth, P., Hattangadi-Gluth, J., Holdhoff, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0166 · Cited by 231
Oligodendroglioma: pathology, molecular mechanisms and markers
Wesseling, P., van den Bent, M., & Perry, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1424-1 · Cited by 226
Nie, D., Lu, J., Zhang, H., Adeli, E., Wang, J., Yu, Z., Liu, L., Wang, Q., Wu, J., & Shen, D. (2019) · Scientific Reports · doi:10.1038/s41598-018-37387-9 · Cited by 213
Molecular pathology of tumors of the central nervous system
Kristensen, B. W., Priesterbach-Ackley, L. P., Petersen, J. K., & Wesseling, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz164 · Cited by 213
Weller, M., Stupp, R., Hegi, M. E., van den Bent, M., Tonn, J. C., Sanson, M., Wick, W., & Reifenberger, G. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos206 · Cited by 202
Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis
Luo, X., Zang, X., Yang, L., Huang, J., Liang, F., Rodriguez-Canales, J., Wistuba, I. I., Gazdar, A., Xie, Y., & Xiao, G. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.017 · Cited by 189
Jiang, R., Yin, X., Yang, P., Cheng, L., Hu, J., Jiao, Y., Wang, Y., Fu, X., Shang, L., Li, L., et al. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00868-w · Cited by 188
Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning
van der Voort, S. R., Incekara, F., Wijnenga, M. M. J., Kapsas, G., Gahrmann, R., Schouten, J. W., Nandoe Tewarie, R., Lycklama, G. J., De Witt Hamer, P. C., Eijgelaar, R. S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac166 · Cited by 187
Imaging Correlates of Adult Glioma Genotypes
Smits, M., & van den Bent, M. J. (2017) · Radiology · doi:10.1148/radiol.2017151930 · Cited by 179
Price, M., Ballard, C. A. P., Benedetti, J. R., Kruchko, C., Barnholtz-Sloan, J. S., & Ostrom, Q. T. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf194 · Cited by 173
Diffuse Infiltrating Oligodendroglioma and Astrocytoma
van den Bent, M. J., Smits, M., Kros, J. M., & Chang, S. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6737 · Cited by 172
Djuric, U., Zadeh, G., Aldape, K., & Diamandis, P. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0022-1 · Cited by 171
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics
van den Bent, M. J., Weller, M., Wen, P. Y., Kros, J. M., Aldape, K. D., & Chang, S. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now277 · Cited by 170
Smits, M. (2016) · The British Journal of Radiology · doi:10.1259/bjr.20150857 · Cited by 169
Automated brain histology classification using machine learning
Ker, J., Bai, Y., Lee, H. Y., Rao, J. P., & Wang, L. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.05.019 · Cited by 169
Pediatric low-grade gliomas: implications of the biologic era
Packer, R. J., Pfister, S. M., Bouffet, É., Avery, R. A., Bandopadhayay, P., Bornhorst, M., Bowers, D. C., Ellison, D. W., Fangusaro, J., Foreman, N. K., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now209 · Cited by 168
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 166
Koehler, J. W., Miller, A. D., Miller, C. R., Porter, B. F., Aldape, K., Beck, J. A., Brat, D. J., Cornax, I., Corps, K. N., Frank, C., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly085 · Cited by 165
Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov182 · Cited by 163
IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
Leeper, H. E., Caron, A. A., Decker, P. A., Jenkins, R. B., Lachance, D. H., & Giannini, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4497 · Cited by 158
Wenger, A., Vega, S. F., Kling, T., Bontell, T. O., Jakola, A. S., & Carén, H. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz011 · Cited by 158
Miller, A. D., Miller, C. R., & Rossmeisl, J. H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01151 · Cited by 156
Low, J., Ostrom, Q. T., Cioffi, G., Neff, C., Waite, K. A., Kruchko, C., & Barnholtz‐Sloan, J. S. (2022) · Neuro-Oncology Practice · doi:10.1093/nop/npac015 · Cited by 155
Jin, L., Shi, F., Chun, Q., Chen, H., Ma, Y., Wu, S., Hameed, N. U. F., Mei, C., Lu, J., Zhang, J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa163 · Cited by 142
Schiff, D., van den Bent, M. J., Vogelbaum, M. A., Wick, W., Miller, C. R., TAPHOORN, M. J. B., Pope, W. B., Brown, P. D., Platten, M., Jalali, R., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz033 · Cited by 140
Hamamoto, R., Komatsu, M., Takasawa, K., Asada, K., & Kaneko, S. (2019) · Biomolecules · doi:10.3390/biom10010062 · Cited by 140
Sahm, F., Brandner, S., Bertero, L., Capper, D., French, P. J., Figarella‐Branger, D., Giangaspero, F., Haberler, C., Hegi, M. E., Kristensen, B. W., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad100 · Cited by 139
Molecular classification of gliomas
Masui, K., Mischel, P. S., & Reifenberger, G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00006-2 · Cited by 137
López, P. D. D., Corrales-García, E. M., Martino, J., Aras, E. L., & Dueñas-Polo, M. T. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1631-4 · Cited by 136
Gorlia, T., Wu, W., Wang, M., Baumert, B. G., Mehta, M. P., Buckner, J. C., Shaw, E., Brown, P. D., Stupp, R., Galanis, E., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not117 · Cited by 135
Xing, Z., Yang, X., She, D., Lin, Y., Zhang, Y., & Cao, D. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5171 · Cited by 134
van den Bent, M. J. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou297 · Cited by 128
Cimino, P. J., Zager, M., McFerrin, L., Wirsching, H.-G., Bolouri, H., Hentschel, B., von Deimling, A., Jones, D., Reifenberger, G., Weller, M., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0443-7 · Cited by 126
Price, M., Neff, C., Nagarajan, N., Kruchko, C., Waite, K. A., Cioffi, G., Cordeiro, B., Willmarth, N. E., Peñas-Prado, M., Gilbert, M. R., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae047 · Cited by 122
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Chan, A. K., Yao, Y., Zhang, Z., Chung, N. Y., Liu, J. S.-M., Li, K. K., Shi, Z., Chan, D. T. M., Poon, W. S., Zhou, L., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.94 · Cited by 118
Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort
For POLA Network, Tabouret, É., Nguyễn, A. T., Dehais, C., Carpentier, C., Ducray, F., Idbaïh, A., Mokhtari, K., Jouvet, A., Uro‐Coste, E., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1611-8 · Cited by 116
TERT promoter mutations and telomere length in adult malignant gliomas and recurrences
Heidenreich, B., Rachakonda, P. S., Hosen, M. I., Volz, F., Hemminki, K., Weyerbrock, A., & Kumar, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3329 · Cited by 110
Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy
Djirackor, L., Halldórsson, S., Niehusmann, P., Leske, H., Capper, D., Kuschel, L. P., Pahnke, J., Due‐Tønnessen, B. J., Langmoen, I. A., Sandberg, C. J., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab149 · Cited by 109
The Use of Immunohistochemistry for Biomarker Assessment—Can It Compete with Other Technologies?
Dunstan, R. W., Wharton, K. A., Quigley, C., & Lowe, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311419163 · Cited by 109
Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer
Mesrati, M. H., Behrooz, A. B., Abuhamad, A. Y., & Syahir, A. (2020) · Cells · doi:10.3390/cells9051236 · Cited by 108
Taal, W., Bromberg, J. E. C., & van den Bent, M. J. (2015) · CNS Oncology · doi:10.2217/cns.15.2 · Cited by 107
Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma
Guan, X., Vengoechea, J. E., Zheng, S., Sloan, A. E., Chen, Y., Brat, D. J., O’Neill, B. P., de Groot, J., Yust‐Katz, S., Yung, W.-K. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091216 · Cited by 106
Wesseling, P., Kros, J. M., & Jeuken, J. W. M. (2011) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2011.08.005 · Cited by 103
Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
Laddha, S. V., da Silva, E. M., Robzyk, K., Untch, B. R., Ke, H., Rekhtman, N., Poirier, J. T., Travis, W. D., Tang, L. H., & Chan, C. S. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0214 · Cited by 103
Huse, J. T., Diamond, E. L., Wang, L., & Rosenblum, M. K. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1359-y · Cited by 102
Glioblastoma Therapy in the Age of Molecular Medicine
Geraldo, L. H., Garcia, C., da Fonseca, A. C. C., Dubois, L. G., Spohr, T. C. L. D. S. E., Matias, D., Magalhães, E. S. D. C., do Amaral, R. F., da Rosa, B. G., Grimaldi, I., et al. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.002 · Cited by 101
A basic review on systemic treatment options in WHO grade II-III gliomas
Mair, M. J., Geurts, M., van den Bent, M. J., & Berghoff, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102124 · Cited by 101
Thakur, N., Yoon, H., & Chong, Y. (2020) · Cancers · doi:10.3390/cancers12071884 · Cited by 99
World Health Organization 2016 Classification of Central Nervous System Tumors
Diamandis, P., & Aldape, K. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.003 · Cited by 97
Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype
Patel, S. H., Bansal, A. G., Young, E. B., Batchala, P. P., Patrie, J. T., Lopes, M. B. S., Jain, R., Fadul, C. E., & Schiff, D. (2019) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6102 · Cited by 97
Mancarella, D., & Plass, C. (2021) · Genome Medicine · doi:10.1186/s13073-021-00837-7 · Cited by 94
Delfanti, R. L., Piccioni, D. E., Handwerker, J., Bahrami, N., Krishnan, A., Karunamuni, R. A., Hattangadi-Gluth, J. A., Seibert, T. M., Srikant, A., Jones, K. A., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2613-7 · Cited by 93
Wang, W., Zhao, Y., Teng, L., Yan, J., Guo, Y., Qiu, Y., Ji, Y., Yu, B., Pei, D., Duan, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41195-9 · Cited by 91
Diseases of the Brain, Head and Neck, Spine 2020–2023: Diagnostic Imaging
Hodler, J., Huch, R., & von Schulthess, G. K. (2020) · IDKD Springer series · doi:10.1007/978-3-030-38490-6 · Cited by 89
Bhandari, A., Liong, R., Koppen, J., Murthy, S. V., & Lasocki, A. (2020) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6875 · Cited by 89
van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae107 · Cited by 88
Girardi, F., Matz, M., Stiller, C. A., You, H., Gragera, R. M., Valkov, М. Y., Bulliard, J., De, P., Morrison, D. S., Wanner, M., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac217 · Cited by 88
Vision transformer based classification of gliomas from histopathological images
Göçeri, E. (2023) · Expert Systems with Applications · doi:10.1016/j.eswa.2023.122672 · Cited by 88
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 88
Li, Y., Wei, D., Liu, X., Fan, X., Wang, K., Li, S., Zhang, Z., Ma, K., Qian, T., Jiang, T., et al. (2020) · European Radiology · doi:10.1007/s00330-021-08237-6 · Cited by 87
Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas
Alentorn, A., Marie, Y., Carpentier, C., Boisselier, B., Giry, M., Labussière, M., Mokhtari, K., Hoang‐Xuan, K., Sanson, M., Delattre, J., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos217 · Cited by 85
Hoang, D.-T., Shulman, E. D., Turakulov, R. I., Abdullaev, Z., Singh, O., Campagnolo, E. M., Lalchungnunga, H., Stone, E. A., Nasrallah, M. P., Ruppin, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02995-8 · Cited by 84
Adult Glioma WHO Classification Update, Genomics, and Imaging: What the Radiologists Need to Know
Bai, J., Varghese, J., & Jain, R. (2020) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000234 · Cited by 83
Metadata
- Authors
- van den Bent, M. J.
- Venue
- Acta Neuropathologica
- Published
- 2010-07-20
- Volume
- 120
- Issue
- 3
- Pages
- 297-304
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC2910894
- OpenAlex
- W2112567075
- Cited by
- 577
- References
- 35
- Citations by year
- 2026: 19 · 2025: 36 · 2024: 70 · 2023: 43 · 2022: 43 · 2021: 47 · 2020: 48 · 2019: 52 · 2018: 33 · 2017: 46 · 2016: 44 · 2015: 33 · 2014: 16 · 2013: 16 · 2012: 20
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Reliability and Agreement in Measurement
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- glioma, interobserver variability, histopathological diagnosis, tumor grading, tumor classification, central pathology review, clinical trial interpretation, generalizability, molecular classification, chemotherapy
- MeSH terms
- Brain Neoplasms, Clinical Trials as Topic, Glioma, Humans, Observer Variation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.